Sumitomo Mitsui Trust Group
AXSM icon

Sumitomo Mitsui Trust Group’s Axsome Therapeutics AXSM Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Buy
2,030
+130
+7% +$22.5K ﹤0.01% 982
2025
Q4 		$347K Buy
+1,900
New +$265K ﹤0.01% 998

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group's AXSM Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group increased its Axsome Therapeutics (AXSM) stake by 6.8% in Q1 2026, buying an estimated $22.5K and bringing the position to 2,030 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Sumitomo Mitsui Trust Group first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $347K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 2,030 shares of Axsome Therapeutics worth $343K as of Q1 2026.
  • Sumitomo Mitsui Trust Group bought 130 Axsome Therapeutics shares in Q1 2026, an estimated $22.5K.
  • Axsome Therapeutics made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #982 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Sumitomo Mitsui Trust Group's Axsome Therapeutics position peaked at $347K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.